NASOPHARANGEAL CANCER
Clinical trials for NASOPHARANGEAL CANCER explained in plain language.
Never miss a new study
Get alerted when new NASOPHARANGEAL CANCER trials appear
Sign up with your email to follow new studies for NASOPHARANGEAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer trial questions need for immediate radiation
Disease control Recruiting nowThis study is for people with advanced nasopharyngeal cancer that has spread. It compares two approaches after initial drug therapy: getting radiation to the head and neck area right away versus waiting and only using radiation if the cancer comes back there. The main goal is to …
Matched conditions: NASOPHARANGEAL CANCER
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New cancer trial tests if boosting immune system beats standard chemo
Disease control Recruiting nowThis study compares two treatment approaches for people with high-risk nasopharyngeal cancer that has spread locally. One approach adds immunotherapy drugs to standard chemotherapy and radiation, while the other uses standard chemotherapy alone for maintenance. The goal is to see…
Matched conditions: NASOPHARANGEAL CANCER
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Timing test: does radiation after drugs help beat back returning cancer?
Disease control Recruiting nowThis study is for people whose nasopharyngeal cancer has returned after initial treatment. It tests whether adding radiation therapy immediately after a standard drug combination (immunotherapy plus chemotherapy) is better than waiting to see if it's needed later. The goal is to …
Matched conditions: NASOPHARANGEAL CANCER
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
New hope for tough cancers: observing a promising Drug's Real-World impact
Disease control Recruiting nowThis study aims to see how well the drug T-DXd works in real-world settings for patients with advanced HER2-positive cancers who have already tried other treatments and have no good options left. It will follow about 100 patients with various solid tumors (excluding breast, lung,…
Matched conditions: NASOPHARANGEAL CANCER
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 13, 2026 15:05 UTC